Pfizer and BioNTech companies today announced that clinical trial results showed their coronavirus vaccine to be "safe, well tolerated" and produced a "robust" immune response in children between the ages of five and 11. years.
The companies also announced that they will soon seek regulatory approval from regulatory bodies.
The vaccine would be given at a lower dosage than that used for individuals 12 and older, the companies said in a statement.
The companies also said they would submit their data to regulatory bodies in the European Union, the United States and around the world "as soon as possible".